The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics

CNS Drugs

Volumn 29, Issue 8, 2015, Pages 637-658

  De Hert, Marc ^a   Sermon, Jan ^b   Geerts, Paul ^b   Vansteelandt, Kristof ^a   Peuskens, Joseph ^a   Detraux, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

DRUG CONTINUOUS THERAPY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EARLY INTERVENTION; FOLLOW UP; GOOD CLINICAL PRACTICE; HOSPITAL READMISSION; HUMAN; INJECTION; MENTAL DETERIORATION; META ANALYSIS; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR OCCUPANCY; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT DURATION; DRUG ADMINISTRATION; HOSPITALIZATION; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA; TIME FACTORS;

EID: 84942980678     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0269-4     Document Type: Review

References (196)

1. Sabaté E, World Health Organization (2003). Adherence to long-term therapies. Evidence for action. WHO Library Cataloguing-in-Publication Data.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
3. Gaebel W, Riesbeck M. Are there clinically useful predictors and early warning signs for pending relapse? Schizophr Res. 2014;152(2-3):469-77.
4. Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1-3):116-28.
5. Doyle R, Turner N, Fanning F, et al. First-episode psychosis and disengagement from treatment: a systematic review. Psychiatr Serv. 2014;65(5):603-11.
6. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53-9.
7. Birchwood M, Macmillan F. Early intervention in schizophrenia. Aust N Z J Psychiatry. 1993;27(3):374-8.
8. Edwards J, Harris MG, Bapat S. Developing services for first-episode psychosis and the critical period. Br J Psychiatry Suppl. 2005;48:s91-7.
9. Bartholomeusz CF, Allott K. Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence. Schizophr Res Treat. 2012;2012:815315.
10. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Recommendation PORT update. Schizophr Bull. 2010;36(1):94-103.
11. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2-44.
12. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012;134(2-3):219-25.
13. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216-26.
14. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
15. Lieberman JA, Stroup TS, McEvoy JP, The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
16. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-53.
17. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 2005;79(1):59-68.
18. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298(6679):985-90.
19. Bleuler M. The long-term course of schizophrenic psychoses. In: Wynne L, Cromwell RL, Matthysse S, editors. The nature of schizophrenia: new approaches to research and treatment. New York: Wiley; 1978. p. 631-651.
20. Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatry. 1980;136(5):413-20.
21. Carpenter WT Jr, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry. 1987;144(11):1466-70.
22. Carpenter WT, Stephens J, Rey A, Hanlon TE, Heinrichs DW. Early intervention versus continuous pharmacotherapy in schizophrenia. Psychopharmacol Bull. 1982;18(1):21-3.
23. Herz MI, Szymanski HV, Simon JC. Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry. 1982;139(7):918-22.
24. Pietzcker A, Gaebel W, Kopcke M, et al. A German multicentre study of the neuroleptic long term therapy of schizophrenic patients; preliminary report. Pharmacopsychiatry. 1986;19(4):161-6.
25. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147(9):1138-48.
26. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301(6756):837-42.
27. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry. 1991;48(4):333-9.
28. Pietzcker A, Gaebel W, Köpcke W, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2-year results of a German multicenter study. J Psychiatr Res. 1993;27(4):321-39.
29. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654-61.
30. Gaebel W. Intermittent medication-an alternative? Acta Psychiatr Scand Suppl. 1994;382:33-8.
31. Gaebel W, Jänner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res. 2002;53(1-2):145-59.
32. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41.
33. Bola JR, Mosher LR. At issue: predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophr Bull. 2002;28(4):559-75.
34. Bola JR, Mosher LR. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Dis. 2003;191(4):219-29.
35. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913-20.
36. Wyatt RJ, Damiani LM, Henter ID. First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry Suppl. 1998;172(33):77-83.
37. Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl. 1989;15:1-46.
38. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75-85.
39. Wieselgren IM, Lindstrom LH. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand. 1996;93(1):9-19.
40. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
41. Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull. 1980;6(4):606-18.
42. Huber G, Gross G, Schüttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6(4):592-605.
43. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144(6):727-35.
44. Lehtinen V, Aaltonen J, Koffert T, Räkköläinen V, Syvälahti E. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? Eur Psychiatry. 2000;15(5):312-20.
45. Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007-16.
46. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis. 2007;195(5):406-14.
47. Moilanen J, Haapea M, Miettunen J, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry. 2013;28(1):53-8.
48. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med. 2012;42(10):2145-55.
49. Harrow M, Grossman LS, Jobe TH, Herbener ES. Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull. 2005;31(3):723-34.
50. Sfera A. Targeted intermittent treatment in chronic schizophrenia. Front Psychiatry. 2013;4:13.
51. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3-13.
52. Iyo M, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013;33(3):398-404.
53. Fallon P, Dursun S, Deakin B. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012;2(1):13-22.
54. Kimura H, Kanahara N, Komatsu N, et al. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2014;155(1-3):52-8.
55. Morrison AP, Hutton P, Shiers D, Turkington D. Antipsychotics: is it time to introduce patient choice? Br J Psychiatry. 2012;201:83-4.
56. Jones N. Embracing patient choice. Br J Psychiatry. 2012;201(6):492.
57. Callard F. Embracing patient choice. Br J Psychiatry. 2012;201(6):493.
58. McNulty J. Medication-free research in early episode schizophrenia: why on earth would I choose to participate in such research? Schizophr Bull. 2006;32(2):305-6.
59. McGlashan TH. Rationale and parameters for medication-free research in psychosis. Schizophr Bull. 2006;32(2):300-2.
60. Chen DT, Moreno JD. Ethics of medication-free research in schizophrenia. Schizophr Bull. 2006;32(2):307-9.
61. Jeste DV. Can medication-free research ever be ethical in older people with psychotic disorders? Schizophr Bull. 2006;32(2):303-4.
62. Goldberg SC, Shenoy RS, Sadler A, Hamer R, Ross B. The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics [proceedings]. Psychopharmacol Bull. 1981;17(1):116-7.
63. Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol. 1981;1(3):141-5.
64. Remington G, Seeman P, Shammi C, Mann S, Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol. 2005;25(6):611-3.
65. National Institute for Health and Clinical Excellence Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). 2009. http://guidance.nice.org.uk/CG82/NICEGuidance/pdf/English. Last update 25 Jan 2013.
66. Chiles JA, Sterchi D, Hyde T, Herz MI. Intermittent medication for schizophrenic outpatients: who is eligible? Schizophr Bull. 1989;15(1):117-21.
67. Sampson S, Joshi K, Mansour M, Adams CE. Intermittent drug techniques for schizophrenia. Schizophr Bull. 2013;39(5):960-1.
68. Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev. 2013;7:CD006196.
69. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry. 2002;7(3):317-21.
70. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;5:CD008016.
71. Emsley R, Fleischhacker WW. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified? Schizophr Res. 2013;150(2-3):427-33.
72. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2-3):408-14.
73. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49-55.
74. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12-21.
75. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
76. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks: Sage Publications; 2001.
77. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
78. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
79. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997;54(5):453-63.
80. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-24.
81. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349-55.
82. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-17.
83. Chen EY, Hui CL, Lam MM, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010;341:c4024.
84. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
85. Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont). 2007;4(11):34-50.
86. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-56.
87. Beasley CM Jr, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 2003;23(6):582-94.
88. Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207-15.
89. Cooper SJ, Butler A, Tweed J, Welch C, Raniwalla J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology. 2000;150(3):237-43.
90. Sampath G, Shah A, Krska J, Soni SD. Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Hum Psychopharmacol. 1992;7:255-64.
91. Eklund K, Forsman A. Minimal effective dose and relapse-double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol. 1991;14(Suppl 2):S7-12.
92. Ruskin PE, Nyman G. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial. J Nerv Ment Dis. 1991;179(4):212-4.
93. McCreadie RG, Wiles D, Grant S, et al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand. 1989;80(6):597-602.
94. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148:120-7.
95. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982;39(1):70-3.
96. Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine. Psychopharmacology. 1984;82(3):153-6.
97. Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology. 1982;77(4):301-4.
98. Odejide OA, Aderounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry. 1982;43(5):195-6.
99. Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand. 1981;64(1):65-84.
100. Kane JM, Rifkin A, Quitkin F, et al. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Res. 1979;1(3):341-8.
101. Rifkin A, Quitkin F, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Arch Gen Psychiatry. 1977;34(10):1215-9.
102. Clark ML, Huber WK, Hill D, Wood F, Costiloe JP. Pimozide in chronic schizophrenic outpatients. Dis Nerv Syst. 1975;36(3):137-41.
103. Roelofs GA. Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation. Acta Psychiatr Scand. 1974;50(2):219-24.
104. Vandecasteele AJ, Vereecken JL. A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia. Acta Psychiatr Scand. 1974;50(3):346-53.
105. Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Arch Gen Psychiatry. 1973;28(1):54-64.
106. Denijs EL, Vereecken JL. Pimozide (orap, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up. Psychiatr Neurol Neurochir. 1973;76(1):47-59.
107. Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J. 1973;1(5854):633-7.
108. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. Br Med J. 1971;3(5775):599-604.
109. Prien RF, Levine J, Cole JO. High dose trifluoperazine therapy in chronic schizophrenia. Am J Psychiatry. 1969;126(3):305-13.
110. Morton MR. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. Am J Psychiatry. 1968;124(11):1585-8.
111. Prien RF, Cole JO, Belkin NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. Br J Psychiatry. 1968;115(523):679-86.
112. Marjerrison G, Irvine D, Stewart CN, Williams R, Matheu H, Demay M. Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients. Can Psychiatr Assoc J. 1964;60:290-8.
113. Troshinsky CH, Aaronson HG, Stone RK. Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psych Bull. 1962;2:11-5.
114. Freeman LS, Alson E. Prolonged withdrawal of chlorpromazine in chronic patients. Dis Nerv Syst. 1962;23:522-5.
115. Gross M, Hitchman IL, Reevs WP, Lawrence J, Newell PC. Discontinuation of treatment with ataractic drugs. A preliminary report. Am J Psychiatry. 1960;116:931-2.
116. Boonstra G, Burger H, Grobbee DE, Kahn RS. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract. 2011;15(2):128-34.
117. Gaebel W, Riesbeck M, Wölwer W, et al. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011;72(2):205-18.
118. Wiedemann G, Hahlweg K, Müller U, Feinstein E, Hank G, Dose M. Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2001;251:72-84.
119. Gaebel W, Möller HJ, Buchkremer G, et al. Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254(2):129-40.
120. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1-3):1-23.
121. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-22.
122. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52(3):173-88.
123. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22.
124. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry. 2012;73(4):e541-7.
125. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007;95(1-3):19-29.
126. Gleeson JF, Rawlings D, Jackson HJ, McGorry PD. Early warning signs of relapse following a first episode of psychosis. Schizophr Res. 2005;80(1):107-11.
127. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835-42.
128. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 9):5-9.
129. Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L. Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol. 2013;33(1):80-3.
130. Case M, Stauffer VL, Ascher-Svanum H, et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. In: Poster presented at the SIRS (Schizophrenia International Research Society) Congress at Florence, Italy, April 10-14, 2010.
131. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-7.
132. Dubois V, Peuskens J, Geerts P, Detraux J. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early Interv Psychiatry. 2014;8:39-49.
133. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000;71(4):373-84.
134. Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7(3):247-54.
135. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609-15.
136. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128-37.
137. Lewis DA. Antipsychotic medications and brain volume: do we have cause for concern? Arch Gen Psychiatry. 2011;68(2):126-7.
138. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656-63.
139. Bartzokis G, Lu PH, Amar CP, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res. 2011;132(1):35-41.
140. Bartzokis G, Lu PH, Raven EP, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res. 2012;140(1-3):122-8.
141. Emsley R. The true cost of non-adherence in schizophrenia. M&B. 2010;1(2):17-21.
142. Mitchell AJ, Selmes T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treatment. 2007;13:336-46.
143. Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30(3):286-97.
144. Hüther J, von Wolff A, Stange D, et al. Incomplete medication adherence of chronically ill patients in German primary care. Patient Prefer Adherence. 2013;7:237-44.
145. Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275-84.
146. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23(10):2305-12.
147. Hansen RA, Maciejewski M, Yu-Isenberg K, Farley JF. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. Psychiatr Serv. 2012;63(9):920-8.
148. Kim B, Lee SH, Yang YK, Park JI, Chung YC. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr Res Treat. 2012;2012:560836.
149. Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013;36(6):651-9.
150. Marder SR. Monitoring treatment and managing adherence in schizophrenia. J Clin Psychiatry. 2013;74(10):e21.
151. Dixon L, Lewis-Fernandez R, Goldman H, Interian A, Michaels A, Kiley MC. Adherence disparities in mental health: opportunities and challenges. J Nerv Ment Dis. 2011;199(10):815-20.
152. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
153. Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
154. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63-7.
155. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132-91.
156. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39(1-2):1-30.
157. Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry. 2014;29(Suppl 2):1409-13.
158. Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19(1):3-5.
159. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.
160. Lambert TJR. Practical management of schizophrenia: the role of long-acting antipsychotics. Int Clin Psychopharmacol. 2013. doi: 10.1097/YIC.0b013e32835ab399
161. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-9.
162. Parellada E. Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacol Bull. 2007;40(2):82-100.
163. De Berardis D, Marini S, Carano A, et al. Efficacy and safety of long acting injectable atypical antipsychotics: a review. Curr Clin Pharmacol. 2013;8(3):256-64.
164. Manchanda R, Chue P, Malla A, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry. 2013;58(5 Suppl 1):5S-13S.
165. Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-80.
166. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378-86.
167. Macfadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol. 2010;25(2):75-82.
168. Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1231-5.
169. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008;23(6):325-31.
170. Viala A, Cornic F, Vacheron MN. Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. Schizophr Res Treat. 2012;2012:368687.
171. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66:S37-41.
172. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568-75.
173. Alphs L, Schooler N, Lauriello J. How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectableantipsychotic treatments for schizophrenia. Schizophr Res. 2014;156:228-32.
174. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134(2-3):187-94.
175. Přikryl R, Přikrylová Kučerová H, Vrzalová M, Cešková E. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treat. 2012;2012:764769.
176. Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013;12(1):22.
177. Samtani MN, Sheehan JJ, Fu DJ, Remmerie B, Sliwa JK, Alphs L. Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clin Pharmacol. 2012;4:25-40.
178. Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7-8):17-23.
179. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-51.
180. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.
181. Kishimoto T, Nitta M, Mimura M, Kane JM, Correll CU. Long acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of cohort studies. Nihon Shinkei Seishin Yakurigaku Zasshi. 2014;34(2):61-2.
182. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-65.
183. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(8):1042-8.
184. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006;(1):CD000459.
185. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041-50.
186. Beasley CM Jr, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? J Clin Psychopharmacol. 2006;26(1):40-4.
187. Matei VP, Mihailescu AI, Davidson M. Is non-pharmacological treatment an option for certain schizophrenia patients? Psychiatr Danub. 2014;26(4):308-13.
188. Mosher LR. Soteria and other alternatives to acute psychiatric hospitalization: a personal and professional review. J Nerv Ment Dis. 1999;187(3):142-9.
189. Mosher LR, Menn AZ. Community residential treatment for schizophrenia: two-year follow-up. Hosp Community Psychiatry. 1978;29(11):715-23.
190. Carpenter WT Jr, Buchanan RW. Commentary on the Soteria project: misguided therapeutics. Schizophr Bull. 2002;28(4):577-81 (discussion 583-8).
191. Bola JR, Mosher LR. Clashing ideologies or scientific discourse? Schizophr Bull. 2002;28(4):583-8.
192. Harrow M, Jobe TH. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull. 2013;39(5):962-5.
193. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther. 2011;17(2):118-32.
194. Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schizophr Res. 2014;152(2-3):381-90.
195. Altamura AC, Aguglia E, Bassi M, et al. Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol. 2012;27(6):336-49.
196. Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry. 2014;71(6):706-15.